Deep Learning-Based Virtual Screening Identifies Potential Small-Molecule Inhibitors of ASK1: Natural Product Lead Discovery for MASH
Open Access
- 20 July 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6438
Abstract
Apoptosis signal-regulating kinase 1 (ASK1) represents a critical therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH). Natural products, owing to their unique chemical diversity, constitute a rich reservoir for discovering novel ASK1 inhibitors. The emergence of artificial intelligence-assisted drug discovery (AIDD) has opened new avenues for exploring small-molecule inhibitors. Through virtual screening, molecular docking, interaction profiling, molecular dynamics simulations, and MM-GBSA binding free energy calculations, we systematically evaluated the binding mode, stability, and key residue contributions of the CMNPD10921–ASK1 complex. CMNPD10921 stably occupied the ASK1 active pocket, forming hydrophobic interactions and hydrogen bonds with multiple key amino acid residues. MM-GBSA analysis yielded a total computed binding free energy of −31.15 kcal/mol, suggesting a computationally favorable interaction, with van der Waals forces serving as the dominant energetic driver of complex stabilization. Residue energy decomposition further identified ILE324, THR288, and THR639 as major contributors to ligand binding. Integrating deep learning, molecular simulation, and quantum chemical calculations, this study successfully identified CMNPD10921 from a vast natural product library as a putative lead compound candidate targeting the ASK1 central regulatory region, offering a novel candidate molecule for anti-MASH drug development.Keywords
Funding Information
- Shenzhen Science and Technology Program (JCYJ20250604150048016)
- Shenzhen Science and Technology Program (JCYJ20240813152313019)
- National Natural Science Foundation of China (82374531)
This publication has 31 references indexed in Scilit:
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Journal of Hepatology, 2024
- Computational approaches streamlining drug discoveryNature, 2023
- Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology, 2022
- gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACSJournal of Chemical Theory and Computation, 2021
- Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPARγ binodal complementary modulesRedox Biology, 2021
- TNF‐α‐Induce Protein 8–Like 1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of Apoptosis Signal–Regulating Kinase 1Hepatology, 2021
- Natural products in drug discovery: advances and opportunitiesNature Reviews Drug Discovery, 2021
- Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsJournal of Hepatology, 2020
- Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019Journal of Natural Products, 2020
- Multiwfn: A multifunctional wavefunction analyzerJournal of Computational Chemistry, 2011